H2AX and cancer: In a previous study, we have shown that delivery in cells of antigen-binding fragments (Fabs) derived from an anti-γ-H2AX monoclonal antibody (mAb) allows the fate of cancer cells after treatment with varying RS-inducing drug combinations to be followed [21].